The stock of Protagenic Therapeutics Inc (PTIX) has seen a 4.64% increase in the past week, with a 10.58% gain in the past month, and a -12.22% decrease in the past quarter. The volatility ratio for the week is 25.30%, and the volatility levels for the past 30 days are at 18.89% for PTIX. The simple moving average for the past 20 days is 13.92% for PTIX’s stock, with a -22.26% simple moving average for the past 200 days.
Is It Worth Investing in Protagenic Therapeutics Inc (NASDAQ: PTIX) Right Now?
There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PTIX is 3.49M, and at present, short sellers hold a 0.29% of that float. The average trading volume of PTIX on September 16, 2024 was 221.89K shares.
PTIX) stock’s latest price update
The stock of Protagenic Therapeutics Inc (NASDAQ: PTIX) has decreased by -9.20 when compared to last closing price of 0.87.Despite this, the company has seen a gain of 4.64% in its stock price over the last five trading days. accesswire.com reported 2024-05-01 that NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1 trial involving PT00114, its synthetic stress-regulating peptide, for treating neuropsychiatric disorders. This marks a significant milestone with the enrollment of 30 subjects across five cohorts, receiving doses up to 1,000 micrograms.
PTIX Trading at 11.46% from the 50-Day Moving Average
After a stumble in the market that brought PTIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.10% of loss for the given period.
Volatility was left at 18.89%, however, over the last 30 days, the volatility rate increased by 25.30%, as shares surge +24.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.27% upper at present.
During the last 5 trading sessions, PTIX rose by +4.64%, which changed the moving average for the period of 200-days by -7.60% in comparison to the 20-day moving average, which settled at $0.7012. In addition, Protagenic Therapeutics Inc saw -20.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTIX starting from Arrow Alexander K., who purchase 8,000 shares at the price of $0.81 back on Oct 12 ’23. After this action, Arrow Alexander K. now owns 45,815 shares of Protagenic Therapeutics Inc, valued at $6,480 using the latest closing price.
Stock Fundamentals for PTIX
Current profitability levels for the company are sitting at:
- -1890.52 for the present operating margin
- -15.62 for the gross margin
The net margin for Protagenic Therapeutics Inc stands at -2001.13. The total capital return value is set at -7.63. Equity return is now at value -206.36, with -152.72 for asset returns.
Currently, EBITDA for the company is -4.5 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 813.92. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.03.
Conclusion
In summary, Protagenic Therapeutics Inc (PTIX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
